May 15 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer that has returned or has not responded to prior treatments. (Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
Pre-market 04:58:57 pm | |||
41.77 USD | +1.57% | 41.88 | +0.26% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.59% | 84.67B | |
+42.60% | 748B | |
+33.28% | 598B | |
-5.74% | 356B | |
+17.79% | 325B | |
+3.37% | 283B | |
+17.11% | 245B | |
+9.11% | 211B | |
-3.97% | 209B | |
+6.74% | 165B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- US FDA approves expanded use of Bristol's cancer cell therapy